By PPN News Staff
The FDA approved the first generic of Symbicort (AstraZeneca), budesonide and formoterol fumarate dihydrate (Breyna, Viatris/Kindeva), an inhaled medication used for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD).
Breyna is approved for asthma patients who are 6 years of age and older. This complex generic drug–device combination product, which is a metered-dose inhaler, should not be used to treat acute asthma attacks, the FDA said.